Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02637323 · ClinicalTrials.gov registry record · Phase 2
Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee
A Phase 2 study, sponsored by Pacira Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
NCT02637323 is a Phase 2 study that has completed, run by Pacira Pharmaceuticals. The registered enrollment target is 81 participants.
The verdict
NCT02637323, a Phase 2 study, has completed, sponsored by Pacira Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
Study Summary
The objectives of this study were to characterize the local extent and duration of exposure of TA from FX006 and TCA IR, characterize the systemic PK of FX006 and TCA IR, and assess the safety and general tolerability of a single 5 mL IA injection of 32 mg FX006 relative to 40 mg of TCA IR in patients with OA of the knee.
Interventions
- DRUG FX006 32 mg
- DRUG TCA IR 40
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02637323
The ClinicalTrials.gov registry entry for NCT02637323 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pacira Pharmaceuticals, which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FX006 32 mg is the first listed.
NCT02637323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02637323 about?
NCT02637323 is a clinical study titled "Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee". The objectives of this study were to characterize the local extent and duration of exposure of TA from FX006 and TCA IR, characterize the systemic PK of FX006 and TCA IR, and assess the safety and general tolerability of a single 5 mL IA injection of 32 mg FX006 relative to 40 mg of TCA IR in patien...
What is the current status of trial NCT02637323?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2015-11. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02637323?
The interventions under investigation include: FX006 32 mg (DRUG), TCA IR 40 (DRUG).
Who is sponsoring clinical trial NCT02637323?
This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.